Parallax Volatility Advisers, L.P. Prothena Corp Public LTD CO Call Options Transaction History

Parallax Volatility Advisers, L.P.

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 14, 2023	BUY	$48.26 - $78.59 $106,172 - $172,898	2,200 New	2,200 $150,000
Q4 2022 Feb 14, 2023	BUY	$52.05 - $65.0 $1.04 Million - $1.3 Million	20,000 New	20,000 $1.21 Million
Q3 2021 Nov 15, 2021	BUY	$48.2 - $78.89 $125,320 - $205,114	2,600 New	2,600 $185,000
Q4 2020 Feb 16, 2021	SELL	$10.12 - $13.94 $860,199 - $1.18 Million	-85,000 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$9.93 - $13.47 $844,050 - $1.14 Million	85,000 New	85,000 $849,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $685M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.